A procedural halt in the Drug Enforcement Administration's hearing on marijuana rescheduling has pushed traders to price in a delayed timeline, with contracts for an early 2027 reclassification seeing a significant, albeit low-volume, spike in recent sessions. The move on Friday, October 09, 2026, saw the implied probability of marijuana being lowered from Schedule I "Before Apr 1, 2027" jump to 94%, a 72-percentage-point increase. The repricing follows a late September order by a DEA Administrative Law Judge to stay the hearing proceedings, suggesting the market now sees a near-certain, but not immediate, resolution.
While the magnitude of the April 2027 contract's move is notable, it occurred on minimal trading volume. A broader look at the market shows a consistent upward trend across all six listed deadlines, indicating sustained high confidence that rescheduling will ultimately occur. The market now implies the most likely window for a final decision has shifted from late 2026 to the first half of 2027, as traders digest the impact of the administrative delay.
Distribution Analysis
The Kalshi prediction market, which asks "Will marijuana be rescheduled?," is structured as a series of contracts with different deadlines. In the session ending October 9, all six contracts covering deadlines from January 2027 to January 2029 rose, signaling that the procedural stay is viewed as a delay rather than a threat to the final outcome.
| Outcome | Current Prob | Change | Volume |
|---|---|---|---|
| Before Jan 1, 2027 | 9% | +2.5pp | 2,562 |
| Before Apr 1, 2027 | 94% | +72.0pp | 1 |
| Before Jul 1, 2027 | 76% | +34.0pp | 66 |
| Before Oct 1, 2027 | 91% | +26.0pp | 3 |
| Before Jan 1, 2028 | 67% | +5.0pp | 67 |
| Before Jan 20, 2029 | 81% | +4.0pp | 29 |
Net: 6 of 6 contracts rose on a total volume of 2,728, shifting the implied timeline for rescheduling into Q1-Q2 2027 while maintaining a high overall probability of eventual success.
What's Driving the Shift
Administrative Hearing Stayed: The primary catalyst for the repricing is a September 29, 2026, order from DEA Chief Administrative Law Judge Derek C. Julius. He paused the hearing on the proposed rule to reschedule marijuana to Schedule III, pending a decision on a motion from anti-rescheduling parties. This move effectively halts the administrative process that was expected to yield a recommendation on the matter.
GAO Report Introduces Uncertainty: The motion that triggered the stay seeks to add a September 23, 2026, Government Accountability Office (GAO) report to the official record. The report, titled "Drug Scheduling: While DEA Decisions Have Aligned with Recent HHS Recommendations, Both Need Comprehensive Policies," found that the DEA and FDA lack comprehensive written policies for their drug scheduling evaluation processes. The introduction of this report into the proceedings creates uncertainty about the length of the delay and whether it could compel a more extensive review.
Timeline Repricing: The market's reaction reflects a belief that this procedural hurdle pushes the final decision out of 2026. The contract for rescheduling "Before Jan 1, 2027" saw the highest trading volume (2,562) but the smallest probability increase (+2.5pp), settling at just 9%. This suggests strong market conviction that a resolution before year-end is highly unlikely. Conversely, the sharp, low-volume spikes in contracts for early-to-mid 2027 indicate that traders are reallocating probability to that timeframe.
Market Context
This market concerns the broad rescheduling of all marijuana. It is separate from a more limited action taken in April 2026, when the Justice Department issued a final rule placing FDA-approved and state-licensed medical marijuana products into Schedule III. That rule remains in effect.
The current administrative hearing, which ran from June 29 to July 15, 2026, is intended to decide the fate of all other forms of marijuana. The process was initiated following a December 2025 Executive Order directing an expedited rulemaking. The current stay represents the first significant procedural delay since the hearing concluded. The extremely low volume on the April 2027 contract's 72-point surge suggests the new 94% price may not reflect broad market consensus and could be subject to further adjustment as more liquidity enters the market.
What to Watch
The next key date is October 13, 2026, the deadline for the government to file its response to the motion to include the GAO report. Following that filing, Judge Julius will rule on whether to admit the report and permit supplemental briefing, which will determine the length of the delay. The final settlement of these contracts depends on an official rescheduling action being confirmed by a slate of national news organizations.
